In Vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2683-2690

  Wang, Hengzhuang ^a   Wu, Hong ^a,b   Ciofu, Oana ^b   Song, Zhijun ^a   Høibya, Niels ^a,b,c  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c European Study Group for Biofilms (ESGB)   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; IMIPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; BIOFILM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; IN VIVO STUDY; LIMIT OF DETECTION; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLANKTON; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALGINATES; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOFILMS; CELLS, IMMOBILIZED; COLISTIN; DISEASE MODELS, ANIMAL; FEMALE; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; IMIPENEM; LUNG; MICROBIAL SENSITIVITY TESTS; PLANKTON; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84860195528     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06486-11     Document Type: Article

References (54)

1. Amsterdam D. 2005. Susceptibility testing of antimicrobials in liquid media, p 61-143. In Lorian V (ed), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268. (Pubitemid 34308974)
3. Bagge N, et al. 2002. Constitutive high expression of chromosomal {beta}- lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob. Agents Chemother. 46: 3406-3411. (Pubitemid 35192904)
4. Bagge N, et al. 2004. Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 48:1168 -1174.
5. Bagge N, et al. 2004. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and {beta}-lactamase and alginate production. Antimicrob. Agents Chemother. 48:1175-1187. (Pubitemid 38405471)
6. Bjarnsholt T, et al. 2005. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorumsensing dependent. Microbiology 151:373-383. (Pubitemid 40277742)
7. Blaser J, Vergeres P, Widmer AF, Zimmerli W. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134 -1139.
8. Brinch KS, et al. 2009. Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model. Antimicrob. Agents Chemother. 53:4801- 4808.
9. Ciofu O, et al. 1996. Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics. Clin. Microbiol. Infect. 2:91-98. (Pubitemid 126682680)
10. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Høiby N. 2010. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 156:1108 -1119.
11. Ciofu O, Tolker-Nielsen T. 2011. Antibiotic tolerance and resistance in biofilms, p 215-229. In Bjarnsholt T, Jensen PØ, Moser C, Høiby N (ed), Biofilm infections. Springer, Berlin, Germany.
12. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318 -1322.
13. Craig WA. 1995. Kinetics of antibiotics in relation to effective and convenient outpatient parenteral therapy. Int. J. Antimicrob. Agents 5:19 -22.
14. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
15. Davies DG, et al. 1998. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280:295-298. (Pubitemid 28178075)
16. Driffield K, Miller K, Bostock JM, O'Neill AJ, Chopra I. 2008. Increased mutability of Pseudomonas aeruginosa in biofilms. J. Antimicrob. Chemother. 61:1053-1056. (Pubitemid 351524449)
17. Drusano GL. 1991. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand. J. Infect. Dis. Suppl. 74: 235-248.
18. Dudhani RV, et al. 2010. Elucidation of the pharmacokinetic/ pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob. Agents Chemother. 54:1117-1124.
19. Fiekers JF. 1983. Effects of the aminoglycoside antibiotics, streptomycin and neomycin, on neuromuscular-transmission. 1. Pre-synaptic considerations. J. Pharmacol. Exp. Ther. 225:487- 495.
20. Frederiksen B, Koch C, Høiby N. 1997. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23:330 -335.
21. Fuentes F, Martin M, Izquierdo J, Gomez-Lus M, Prieto J. 1995. In vivo and in vitro study of several pharmacodynamic effects of meropenem. Scand. J. Infect. Dis. 27:469-474.
22. Gerber A, et al. 1983. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J. Infect. Dis. 147:910 -917.
23. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd ed, p 451-457. Marcel Dekker, Inc., New York, NY.
24. Gudmundsson S, Erlendsdottir H, Gottfredsson M, Gudmundsson A. 1990. The postantibiotic effect induced by antimicrobial combinations. Scand. J. Infect. Dis. Suppl. 74:80 -93.
25. Haagensen JAJ, et al. 2007. Differentiation and distribution of colistinand sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa bio- films. J. Bacteriol. 189:28 -37.
26. Hansen MC, Palmer RJ, Jr, Udsen C, White DC, Molin S. 2001. Assessment of GFP fluorescence in cells of Streptococcus gordonii under conditions of low pH and low oxygen concentration. Microbiology 147: 1383-1391. (Pubitemid 32454655)
27. Harmsen M, Lappann M, Knochel S, Molin S. 2010. Role of extracellular DNA during biofilm formation by Listeria monocytogenes. Appl. Environ. Microbiol. 76:2271-2279.
28. Hau J, Hoosier GLV. 2003. Handbook of laboratory animal science, vol. I. Essential principles and practices, p 351-389. CRC Press LLC, Boca Raton, FL.
29. Hau J, Hoosier GLV. 2003. Handbook of laboratory animal science, vol. I. Essential principles and practices, p 413-455. CRC Press LLC, Boca Raton, FL.
30. Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N. 2011. Pharmacokinetics/ pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 55:4469-4474.
31. Herrmann G, et al. 2010. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J. Infect. Dis. 202:1585-1592.
32. Heydorn A, et al. 2002. Statistical analysis of Pseudomonas aeruginosa biofilm development: impact of mutations in genes involved in twitching motility, cell-to-cell signaling, and stationary-phase sigma factor expression. Appl. Environ. Microbiol. 68:2008 -2017.
33. Hoffmann N, et al. 2007. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob. Agents Chemother. 51:3677-3687. (Pubitemid 47519359)
34. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. 2010. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 35:322-332.
35. Høiby N, Johansen H. 1995. Ciprofloxacin in sweat and antibiotic resistance. The Copenhagen Study Group on Antibiotics in Sweat. Lancet 346: 1235.
36. Høiby N, et al. 2001. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 3:23-35. (Pubitemid 32172037)
37. Jaccard C, et al. 1998. Prospective randomized comparison of imipenemcilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob. Agents Chemother. 42:2966 -2972.
38. Jensen PO, et al. 2007. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 153:1329 -1338.
39. Leroy P, Decolin D, Nicolas S, Archimbault P, Nicolas A. 1989. Residue determination of two co-administered antibacterial agents - cephalexin and colistin - in calf tissues using high-performance liquid chromatography and microbiological methods. J. Pharm. Biomed. Anal. 7:1837-1846. (Pubitemid 20253618)
40. Molin S, Tolker-Nielsen T. 2003. Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure. Curr. Opin. Biotechnol. 14:255-261. (Pubitemid 36782653)
41. Mouton JW, Den Hollander J. 1994. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 38:931-936. (Pubitemid 24150817)
42. Mouton JW, Vinks AA, Punt NC. 1997. Pharmacokineticpharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob. Agents Chemother. 41:733-738. (Pubitemid 27150521)
43. Munckhof WJ, Giles C, Turnidge JD. 2001. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria. J. Antimicrob. Chemother. 47:879-883. (Pubitemid 32519839)
44. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. 2008. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol. Microbiol. 68:223-240. (Pubitemid 351363790)
45. Pedersen SS, Shand GH, Hansen BL, Hansen GN. 1990. Induction of experimental chronic Pseudomonas aeruginosa lung infection with P. aeruginosa entrapped in alginate microspheres. APMIS 98:203-211.
46. Plachouras D, et al. 2007. In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 57:419-422. (Pubitemid 46498658)
47. Ratjen F, et al. 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57:306 -311.
48. Rogers GB, Hoffman LR, Doring G. 2011. Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. J. Cyst. Fibros. 10:387- 400.
49. Safdar N, Andes D, Craig WA. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63- 68.
50. Stewart PS. 1996. Theoretical aspects of antibiotic diffusion into microbial biofilms. Antimicrob. Agents Chemother. 40:2517-2522. (Pubitemid 26367635)
51. Turnidge JD. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10 -22.
52. Tyson GW, et al. 2004. Community structure and metabolism through reconstruction of microbial genomes from the environment. Nature 428: 37-43. (Pubitemid 38332350)
53. Vogelman B, Craig WA. 1986. Kinetics of antimicrobial activity. J. Pediatr. 108:835- 840.
54. WuH, et al. 2000. Detection of N-acylhomoserine lactones in lung tissues of mice infected with Pseudomonas aeruginosa. Microbiology 146:2481-2493.